Abstract
Quantitative structure-activity relationships (QSAR) of 65 different molecular series histone deacetylase inhibitors (HDACIs) with only one common pyrrole ring were studied by using comparative molecular field analysis (CoMFA), comparative molecular similarity indices analysis (CoMSIA) and hologram quantitative structure-activity relationship (HQSAR). The leave-one-out cross-validation q2 values of CoMFA, CoMSIA and HQSAR models were 0.623, 0.662 and 0.716, and non-cross-validated r2 values were 0.952, 0.909 and 0.891, respectively. The contour maps and atom contribution map provided helpful visualization information for structural modification of the HDACIs for better activity. A further docking study was carried out by using Surflex-dock method. Sixty-five compounds were docked into histone deacetylase (PDB ID 1T64). A reasonable docking model between inhibitors and the protein was obtained. The interaction between ligands and the receptor can reveal the binding mode of the HDAC inhibitors and HDAC enzyme. According to QSAR and docking results, eight new molecules were proposed, and their activities were predicted by using the established QSAR model and docking method. The results indicated that the proposed potential molecules have a potent activity.
Keywords: CoMFA, CoMSIA, HQSAR, HDACIs, Surflex-dock
Letters in Drug Design & Discovery
Title:QSAR and Docking Studies on Different Series of Histone Deacetylase Inhibitors (HDACIs)
Volume: 9 Issue: 4
Author(s): Yuhong Xiang, Liang Zhang, Zhuoyong Zhang
Affiliation:
Keywords: CoMFA, CoMSIA, HQSAR, HDACIs, Surflex-dock
Abstract: Quantitative structure-activity relationships (QSAR) of 65 different molecular series histone deacetylase inhibitors (HDACIs) with only one common pyrrole ring were studied by using comparative molecular field analysis (CoMFA), comparative molecular similarity indices analysis (CoMSIA) and hologram quantitative structure-activity relationship (HQSAR). The leave-one-out cross-validation q2 values of CoMFA, CoMSIA and HQSAR models were 0.623, 0.662 and 0.716, and non-cross-validated r2 values were 0.952, 0.909 and 0.891, respectively. The contour maps and atom contribution map provided helpful visualization information for structural modification of the HDACIs for better activity. A further docking study was carried out by using Surflex-dock method. Sixty-five compounds were docked into histone deacetylase (PDB ID 1T64). A reasonable docking model between inhibitors and the protein was obtained. The interaction between ligands and the receptor can reveal the binding mode of the HDAC inhibitors and HDAC enzyme. According to QSAR and docking results, eight new molecules were proposed, and their activities were predicted by using the established QSAR model and docking method. The results indicated that the proposed potential molecules have a potent activity.
Export Options
About this article
Cite this article as:
Yuhong Xiang, Liang Zhang, Zhuoyong Zhang , QSAR and Docking Studies on Different Series of Histone Deacetylase Inhibitors (HDACIs), Letters in Drug Design & Discovery 2012; 9(4) . https://dx.doi.org/10.2174/157018012799860033
DOI https://dx.doi.org/10.2174/157018012799860033 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Uric Acid and Hypertension
Current Pharmaceutical Design Inhibitors of the PI3K/Akt/mTOR Pathway: New Hope for Breast Cancer Patients
Recent Patents on Anti-Cancer Drug Discovery Serpins for Diagnosis and Therapy in Cancer
Cardiovascular & Hematological Disorders-Drug Targets Natural and Synthetic Furanocoumarins as Treatment for Vitiligo and Psoriasis
Current Drug Therapy Targeted Drug Delivery: Trends and Perspectives
Current Drug Delivery Interplay between Epigenetics & Cancer Metabolism
Current Pharmaceutical Design Edible Transgenic Plant Vaccines for Different Diseases
Current Pharmaceutical Biotechnology Pharmacogenomics of Breast Cancer Targeted Therapy: Focus on Recent Patents
Recent Patents on DNA & Gene Sequences Pathways Related to the Anti-Cancer Effects of Metabolites Derived from Cerrado Biome Native Plants: An Update and Bioinformatics Analysis on Oral Squamous Cell Carcinoma
Protein & Peptide Letters Histone Modifier Differentially Regulates Gene Expression and Unravels Survival Role of MicroRNA-494 in Jurkat Leukemia
MicroRNA Updates on the Role of FDG-PET/CT in Gynecological Malignancies
Current Molecular Imaging (Discontinued) Heme Oxygenase-1 in Lung Disease
Current Drug Targets Natural Polyphenols and their Synthetic Analogs as Emerging Anticancer Agents
Current Drug Targets Natural Compounds as Anticancer Agents Targeting DNA Topoisomerases
Current Genomics Endocrine Therapy Resistance: Current Status, Possible Mechanisms and Overcoming Strategies
Anti-Cancer Agents in Medicinal Chemistry The Involvement of Post-Translational Modifications in Alzheimer's Disease
Current Alzheimer Research Cutaneous Markers of HIV Infection and Progression
Current HIV Research Genetic Variations in Telomere Maintenance, with Implications on Tissue Renewal Capacity and Chronic Disease Pathologies
Current Pharmacogenomics and Personalized Medicine Molecular Recognition Mechanisms for Detecting Cell Death In Vivo
Current Pharmaceutical Biotechnology Therapeutic Potential of Nucleic Acid-Based Drugs in Coronary Hyper- Proliferative Vascular Diseases
Current Medicinal Chemistry